Brain dysfunction in phenylketonuria: is phenylalanine toxicity the only possible cause?
In phenylketonuria, mental retardation is prevented by a diet that severely restricts natural protein and is supplemented with a phenylalanine-free amino acid mixture. The result is an almost normal outcome, although some neuropsychological disturbances remain. The pathology underlying cognitive dysfunction in phenylketonuria is unknown, although it is clear that the high plasma concentrations of phenylalanine influence the blood-brain barrier transport of large neutral amino acids. The high plasma phenylalanine concentrations increase phenylalanine entry into brain and restrict the entry of other large neutral amino acids. In the literature, emphasis has been on high brain phenylalanine as the pathological substrate that causes mental retardation. Phenylalanine was found to interfere with different cerebral enzyme systems. However, apart from the neurotoxicity of phenylalanine, a deficiency of the other large neutral amino acids in brain may also be an important factor affecting cognitive function in phenylketonuria. Cerebral protein synthesis was found to be disturbed in a mouse model of phenylketonuria and could be caused by shortage of large neutral amino acids instead of high levels of phenylalanine. Therefore, in this review we emphasize the possibility of a different idea about the pathogenesis of mental dysfunction in phenylketonuria patients and the aim of treatment strategies. The aim of treatment in phenylketonuria might be to normalize cerebral concentrations of all large neutral amino acids rather than prevent high cerebral phenylalanine concentrations alone. In-depth studies are necessary to investigate the role of large neutral amino acid deficiencies in brain.
van Spronsen
F J
FJ
Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. f.j.van.spronsen@bkk.umcg.nl
Hoeksma
Marieke
M
Reijngoud
Dirk-Jan
DJ
D021542:Amino Acids, Neutral / Q000172:deficiency / Q000378:metabolism; D000818:Animals; D001812:Blood-Brain Barrier / Q000502:physiology; D001921:Brain / Q000378:metabolism; D001927:Brain Diseases / Q000209:etiology* / Q000378:metabolism / Q000503:physiopathology; D003603:Cytotoxins / Q000009:adverse effects; D006801:Humans; D008954:Models, Biological; D010649:Phenylalanine / Q000009:adverse effects* / Q000097:blood / Q000378:metabolism; D010661:Phenylketonurias / Q000097:blood / Q000150:complications* / Q000503:physiopathology
D021542:Amino Acids, Neutral; D003603:Cytotoxins; D010649:Phenylalanine